LifeMD (LFMD) Stock Forecast & Price Target

LifeMD Inc has demonstrated a robust growth trajectory, with its active telehealth subscriber base increasing by 14% year-over-year to reach 310,818 by the end of the third quarter of 2025. The company's total revenue of $60.2 million reflects a 12.7% year-over-year increase, bolstered by a 17.4% growth in telehealth revenue, which accounted for the majority of this figure. Furthermore, LifeMD's strategic investments in telehealth infrastructure and the introduction of competitively priced products, such as GLP-1s, underscore its potential for continued expansion and revenue generation in the rapidly evolving healthcare market.

LifeMD Inc reported revenue of $60.2 million for the quarter, reflecting a 13% year-over-year growth that fell short of expectations, while adjusted EBITDA of $5.1 million also missed the anticipated figures, signaling challenges in revenue generation. The company's decision to reduce marketing for compounded products has led to slowed revenue growth, compounding concerns regarding the sustainability of its telehealth segment, which now has an adjusted revenue guidance for FY2025 of $192-$193 million. Additionally, various risks, including inability to acquire new patients and heightened competition from lower-cost alternatives, further contribute to a negative outlook on the company's future financial performance.